IND-enabling studies of the potent lpxc inhibitor LPC-233 as a novel antibiotic against gram-negative pathogens
Ended Project Grant Awarded Last action
- Award ID
- R44AI152896
- Recipient
-
Valanbio Therapeutics, Inc. UEI KKFTU8J72323
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,180,429
Award facts
- Assistance listing
- 93.855 Allergy and Infectious Diseases Research
- Completion date
- Originally
- Funding
-
- $2,386,087.00 Federal
- $794,342.00 Non-federal
- Place of performance
- North Carolina, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $794,342 | $0 | |
| Amendment | $794,342 | $794,342 | |
| Amendment | $0 | $0 | |
| Original award | $797,403 | $0 |
Quick answers
Who received award R44AI152896?
R44AI152896 was awarded to Valanbio Therapeutics, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 16, 2020.
How much is award R44AI152896 worth?
$3,180,429 has been obligated on R44AI152896: $2,386,087 in federal funding and $794,342 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award